Cargando…
What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between (89)Zr- and (64)Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model
Although positron emission tomography (PET) imaging with 18-Fluorodeoxyglucose ((18)F-FDG) is a promising technique in multiple myeloma (MM), the development of other radiopharmaceuticals seems relevant. CD138 is currently used as a standard marker for the identification of myeloma cells and could b...
Autores principales: | Bailly, Clément, Gouard, Sébastien, Guérard, François, Chalopin, Benjamin, Carlier, Thomas, Faivre-Chauvet, Alain, Remaud-Le Saëc, Patricia, Bourgeois, Mickaël, Chouin, Nicolas, Rbah-Vidal, Latifa, Tripier, Raphaël, Haddad, Ferid, Kraeber-Bodéré, Françoise, Bodet-Milin, Caroline, Chérel, Michel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567828/ https://www.ncbi.nlm.nih.gov/pubmed/31137758 http://dx.doi.org/10.3390/ijms20102564 |
Ejemplares similares
-
Comparison of Immuno-PET of CD138 and PET imaging with (64)CuCl(2) and (18)F-FDG in a preclinical syngeneic model of multiple myeloma
por: Bailly, Clément, et al.
Publicado: (2018) -
ImmunoPET in Multiple Myeloma—What? So What? Now What?
por: Bailly, Clément, et al.
Publicado: (2020) -
Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease
por: Gouard, Sébastien, et al.
Publicado: (2020) -
Tumor Immunotargeting Using Innovative Radionuclides
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2015) -
Immuno-PET for Clinical Theranostic Approaches
por: Bailly, Clément, et al.
Publicado: (2016)